Cytokeratin 8 + 18 Recombinant Antibody

$Lane 1: Hela cell; Lane 2: MCF-7 cell; Lane 3: A431 cell; Probed with Cytokeratin 8 + 18 (8C12) Monoclonal Antibody (bsm-52419R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: Hela cell; Lane 2: MCF-7 cell; Lane 3: A431 cell; Probed with Cytokeratin 8 + 18 (8C12) Monoclonal Antibody (bsm-52419R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

Flow cytometric analysis of HeLa cells with Cytokeratin 8 + 18 (8C12) Monoclonal Antibody (bsm-52419R) at a 1:50 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

$IF(ICC) staining with CytokeRatin 8+18 (8C12) Monoclonal Antibody (bsm-52419R) at 1:100 in HeLa cells (red). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with CytokeRatin 8+18 (8C12) Monoclonal Antibody (bsm-52419R) at 1:100 in HeLa cells (red). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with CytokeRatin 8+18 (8C12) Monoclonal Antibody (bsm-52419R) at 1:100 in MCF-7 cells (red). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with CytokeRatin 8+18 (8C12) Monoclonal Antibody (bsm-52419R) at 1:100 in MCF-7 cells (red). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with CytokeRatin 8+18 (8C12) Monoclonal Antibody (bsm-52419R) at 1:100 in A431 cells (red). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with CytokeRatin 8+18 (8C12) Monoclonal Antibody (bsm-52419R) at 1:100 in A431 cells (red). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with CytokeRatin 8+18 (8C12) Monoclonal Antibody (bsm-52419R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with CytokeRatin 8+18 (8C12) Monoclonal Antibody (bsm-52419R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human liver tissue incubated with CytokeRatin 8+18 (8C12) Monoclonal Antibody (bsm-52419R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human liver tissue incubated with CytokeRatin 8+18 (8C12) Monoclonal Antibody (bsm-52419R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed, paraffin embedded (human liver); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with (Cytokeratin 8 + 18) Monoclonal Antibody, Unconjugated (bsm-52419R) at 1:200 overnight at 4\u00b0C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.$

Paraformaldehyde-fixed, paraffin embedded (human liver); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with (Cytokeratin 8 + 18) Monoclonal Antibody, Unconjugated (bsm-52419R) at 1:200 overnight at 4\u00b0C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.

$Paraformaldehyde-fixed, paraffin embedded (human colon); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with (Cytokeratin 8 + 18) Monoclonal Antibody, Unconjugated (bsm-52419R) at 1:200 overnight at 4\u00b0C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.$

Paraformaldehyde-fixed, paraffin embedded (human colon); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with (Cytokeratin 8 + 18) Monoclonal Antibody, Unconjugated (bsm-52419R) at 1:200 overnight at 4\u00b0C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.

$Paraformaldehyde-fixed, paraffin embedded (human breast); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with (Cytokeratin 8 + 18) Monoclonal Antibody, Unconjugated (bsm-52419R) at 1:200 overnight at 4\u00b0C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.$

Paraformaldehyde-fixed, paraffin embedded (human breast); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with (Cytokeratin 8 + 18) Monoclonal Antibody, Unconjugated (bsm-52419R) at 1:200 overnight at 4\u00b0C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.

$Paraformaldehyde-fixed, paraffin embedded (human lung carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with (Cytokeratin 8 + 18) Monoclonal Antibody, Unconjugated (bsm-52419R) at 1:200 overnight at 4\u00b0C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.$

Paraformaldehyde-fixed, paraffin embedded (human lung carcinoma); Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15min; Block endogenous peroxidase by 3% hydrogen peroxide for 20 minutes; Blocking buffer (normal goat serum) at 37\u00b0C for 30min; Antibody incubation with (Cytokeratin 8 + 18) Monoclonal Antibody, Unconjugated (bsm-52419R) at 1:200 overnight at 4\u00b0C, followed by operating according to SP Kit(Rabbit) (sp-0023) instructionsand DAB staining.

$Lane 1: Human MCF-7 cell lysates; Lane 2: Human SW480 cell lysates; Lane 3: Human HepG2 cell lysates; Lane 4: Human HeLa cell lysates probed with Cytokeratin 8 Monoclonal Antibody, Unconjugated (bsm-52419R) at 1:2000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.$

Lane 1: Human MCF-7 cell lysates; Lane 2: Human SW480 cell lysates; Lane 3: Human HepG2 cell lysates; Lane 4: Human HeLa cell lysates probed with Cytokeratin 8 Monoclonal Antibody, Unconjugated (bsm-52419R) at 1:2000 dilution and 4\u00b0C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.

Applications

WB
FCM
IHC-P
IF(ICC)
IHC

Reactivity

Human
Mouse

Overview
Catalog #	bsm-52419r-100ul
Product Name	Cytokeratin 8 + 18 Recombinant Antibody
Applications	WB, FCM, IHC-P, IF(ICC), IHC
Reactivity	Human, Mouse
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Full length protein
Clonality	Recombinant
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20°C for 12 months.
Target
Swiss Prot	P05783, P05787
Synonyms	KeRatin, type II cytoskeletal 8, CytokeRatin-8, KeRatin-8, Type-II keRatin Kb8, KeRatin, type I cytoskeletal 18, Cell prolifeRation-inducing gene 46 protein, CytokeRatin-18, KeRatin-18, CK-8, K8, KRT8, CYK8, CK-18, K18, KRT18, CYK18
Background	Cytokeratins comprise a diverse group of intermediate filament proteins (IFPs) that are expressed as pairs in both keratinized and non-keratinized epithelial tissue. Cytokeratins play a critical role in differentiation and tissue specialization and function to maintain the overall structural integrity of epithelial cells. They have been found to be useful markers of tissue differentiation, which is directly applicable to the characterization of malignant tumors. Cytokeratin 8 expression is seen in epithelium and epithelium-derived tumors. The Cytokeratin 8 and 18 pair are normally expressed in simple epithelia, but not in stratified epithelial cells. Research indicates that squamous cell carcinomas derived from stratified epithelia show abnormal expression of Cytokeratin 8 and 18, although it is not known whether these proteins contribute to the malignant phenotype of the cells. Expression of Cytokeratin 8 and 18 in oral squamous cell carcinomas is an independent prognostic marker that indicates a poor prognosis. Cytokeratin 8 expression correlates with malignancy in leukoplakia and carcinomas of the head and neck; it is expressed in all non-small-cell lung cancers. Cytokeratin 8 has been shown to possess extracellular epitopes on tumor cells, which may represent valuable targets for therapy.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(ICC)	1:50-200
IHC